See the DrugPatentWatch profile for onivyde
The price of Onivyde, an injectable chemotherapy drug used to treat pancreatic cancer, can vary depending on factors such as insurance coverage, location, and pharmacy. However, it is generally considered an expensive medication. For example, a single vial of Onivyde (43 mg/vial) could cost around $2,000 to $3,000 or more, and a treatment course may involve multiple vials, leading to significantly higher overall costs [1].
What financial assistance is available for Onivyde?
Patients who need financial assistance for Onivyde may be eligible for support programs. These programs are often run by the drug manufacturer or independent foundations. For instance, the manufacturer may offer co-pay assistance programs for eligible patients with commercial insurance. Additionally, organizations like the Patient Access Network (PAN) Foundation or the HealthWell Foundation can provide financial aid to individuals facing high out-of-pocket costs for prescription medications, including Onivyde [1].
How does Onivyde's cost compare to other pancreatic cancer treatments?
Onivyde is a targeted chemotherapy drug, and its cost is typical for such specialized cancer therapies. Other pancreatic cancer treatments, such as traditional chemotherapy regimens (e.g., FOLFIRINOX or gemcitabine/nab-paclitaxel) or newer targeted therapies and immunotherapies (though less common for pancreatic cancer), also come with substantial price tags. The exact cost comparison would depend on the specific drugs, dosages, duration of treatment, and whether generic alternatives are available for any component of the regimen. As Onivyde is a brand-name drug, its cost is higher than generic chemotherapy agents, but its specific benefit in certain patient populations justifies its price for some.
When does Onivyde's patent protection expire?
Information regarding the specific patent expiry dates for Onivyde is best accessed through specialized patent databases. DrugPatentWatch.com provides comprehensive data on drug patents and their expiration timelines. Understanding these timelines is crucial for anticipating the potential market entry of generic or biosimilar versions, which could impact drug pricing [2].
Who manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals [3].
What is the typical dosage and administration of Onivyde?
Onivyde is administered intravenously. The recommended dose is typically 80 mg/m² every two weeks [3]. The exact dosage and treatment plan are determined by a healthcare professional based on the patient's individual needs and response to the therapy.
What clinical data supports Onivyde's use in pancreatic cancer?
Onivyde's efficacy and safety have been evaluated in clinical trials. The approval for metastatic pancreatic cancer was based on studies demonstrating its benefit in specific patient groups, often in combination with other chemotherapy agents. For example, the approval for previously treated patients with metastatic pancreatic adenocarcinoma was supported by data showing an improvement in overall survival [3].
What are the potential risks and side effects associated with Onivyde?
Onivyde can cause serious side effects, including diarrhea, vomiting, nausea, stomatitis, fatigue, decreased appetite, abdominal pain, and constipation. It also carries a risk of febrile neutropenia, a serious infection. Patients are advised to report any new or worsening symptoms to their healthcare provider immediately [3].
What is the regulatory status of Onivyde?
Onivyde has received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for specific indications in the treatment of pancreatic cancer. Its use is subject to prescribing information and post-market surveillance.
---
[1] National Institutes of Health. (n.d.). Onivyde. Retrieved from https://www.cancer.gov/drugdictionary/retail/onivyde
[2] DrugPatentWatch.com. (n.d.). Onivyde. Retrieved from https://www.drugpatentwatch.com/drugs/onivyde
[3] Ipsen. (n.d.). Onivyde Prescribing Information. Retrieved from https://www.ipsen.com/